Out of Board Meeting For approval of Financial Results for Quarter ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Deccan Health Care Ltd's board, meeting on November 14, 2025, approved standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025. Standalone revenue grew strongly at ~35% YoY to ₹4,587.41 lakhs for H1 FY26 (vs ₹3,388.19 lakhs in H1 FY25), while Q2 FY26 standalone revenue rose to ₹2,440.46 lakhs (up ~13.7% YoY). Standalone Q2 PAT surged ~67% YoY to ₹89.97 lakhs, and H1 FY26 PAT grew to ₹111.22 lakhs. Consolidated figures tracked closely, with H1 FY26 PAT of ₹115.11 lakhs. The statutory auditor (Keyur Shah & Associates) issued an unqualified limited review report on both sets. However, operating cash flow deteriorated sharply — standalone net cash used in operations was -₹308.36 lakhs (vs -₹142.93 lakhs a year earlier), reflecting a 32% jump in trade receivables (to ₹1,661.58 lakhs) and a ~24% rise in other current assets since March 2025.
Headline revenue and profit growth looks robust, but the widening negative operating cash flow and swelling receivables suggest earnings quality may be weaker than the P&L implies — worth watching for collection and working capital trends.